Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Daiichi Sankyo to Independently Market Memantine
November 15, 2010
- Otsuka Changes Articles of Incorporation
November 15, 2010
- All-Patient Drug Use-Result Survey on Humira Completed
November 15, 2010
- Combined Half-Year Sales of Top-Eight Domestic Firms Up 1.8%
November 15, 2010
- Nippon Kayaku Ties Up with Celltrion to Develop Herceptin, Remicade Biosimilars
November 15, 2010
- Osteoporosis GL to Be Revised in 2011
November 15, 2010
- Astellas: Sales, Profits Down Due to Prograf Patent Expiration
November 15, 2010
- Savings by Generic Substitutionto to Taper Off: Mr Masuhara
November 15, 2010
- GSK Reduces Price of Cervarix by 30% in Canada
November 15, 2010
- Taisho: Sales Down 1% for Pharma, Up 4.6% for Self-Med
November 15, 2010
- Korosho OKs Continued Sale of Mylotarg in Japan
November 15, 2010
- Eisai to Increase Market Share for Higher-Strength Aricept
November 15, 2010
- Shionogi: Sales Up 8.1%, Net Profits Down 40.8%
November 15, 2010
- Crohn's Disease, Ankylosing Spondylitis Approved for Humira: Abbott, Eisai
November 15, 2010
- MTPC, Korosho Discussing Resumptionof of Marketing for Medway Inj.
November 15, 2010
- Ono: Sales Down 5.1% Due to Price Cuts, Competition with Generics
November 15, 2010
- Chuikyo Appreciates Efforts Made to Develop, Apply for Unapproved Drugs/Indications
November 15, 2010
- Shionogi Confident about Its Marketing Strategy in Japan
November 15, 2010
- Kissei: Long-Listed Products Struggle due to NHI Price Cuts
November 15, 2010
- Lucentis Recommended for Approval in EU for DME: Novartis
November 15, 2010
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…